• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Analysis of Body Mass Index and Clinicopathological Factors in Patients with Papillary Thyroid Carcinoma.甲状腺乳头状癌患者的体重指数与临床病理因素分析
Diabetes Metab Syndr Obes. 2024 May 13;17:2013-2019. doi: 10.2147/DMSO.S453468. eCollection 2024.
2
Correlation Between the Clinicopathological Features of Papillary Thyroid Carcinoma Complicated with Hashimoto's Thyroiditis, BRAF V600E Gene Mutation, and RET Gene Rearrangement.桥本甲状腺炎合并甲状腺乳头状癌的临床病理特征与 BRAF V600E 基因突变、RET 基因重排的相关性。
J Coll Physicians Surg Pak. 2024 Apr;34(4):445-450. doi: 10.29271/jcpsp.2024.04.445.
3
Integrating BRAF mutation, ultrasonic and clinicopathologic characteristics for predicting the risk of cervical central lymph node metastasis in papillary thyroid carcinoma.整合 BRAF 突变、超声及临床病理特征预测甲状腺乳头状癌中央区淋巴结转移风险
BMC Cancer. 2022 Apr 27;22(1):461. doi: 10.1186/s12885-022-09550-z.
4
Association of Body Mass Index With Clinicopathological Features of Papillary Thyroid Carcinoma: A Retrospective Study.体重指数与甲状腺乳头状癌临床病理特征的相关性:一项回顾性研究。
Endocr Pract. 2023 Feb;29(2):83-88. doi: 10.1016/j.eprac.2022.11.012. Epub 2022 Dec 5.
5
Prevalence and Impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto's thyroiditis: a systematic review with meta-analysis.伴有桥本甲状腺炎的甲状腺乳头状癌患者 BRAF 突变的流行率和影响:系统评价和荟萃分析。
Front Endocrinol (Lausanne). 2023 Nov 17;14:1273498. doi: 10.3389/fendo.2023.1273498. eCollection 2023.
6
Combined effect of Hashimoto's thyroiditis and BRAF(V600E) mutation status on aggressiveness in papillary thyroid cancer.桥本甲状腺炎与BRAF(V600E)突变状态对甲状腺乳头状癌侵袭性的联合影响
Head Neck. 2016 Jan;38(1):95-101. doi: 10.1002/hed.23854. Epub 2015 Jun 26.
7
Prevalence and impact of non-alcoholic fatty liver disease in patients with papillary thyroid carcinoma.甲状腺乳头状癌患者中非酒精性脂肪性肝病的患病率及其影响。
Endocrine. 2023 Jun;80(3):619-629. doi: 10.1007/s12020-023-03312-y. Epub 2023 Jan 25.
8
Analysis of Gene Mutation in Hashimoto's Thyroiditis With Multifocal Papillary Thyroid Carcinoma.多灶性甲状腺乳头状癌合并桥本甲状腺炎的基因突变分析
Am Surg. 2025 Feb;91(2):186-190. doi: 10.1177/00031348241282710. Epub 2024 Sep 9.
9
[Clinical pathological characteristics of resectable papillary thyroid microcarcinoma].可切除性甲状腺微小乳头状癌的临床病理特征
Zhonghua Zhong Liu Za Zhi. 2017 May 23;39(5):361-366. doi: 10.3760/cma.j.issn.0253-3766.2017.05.008.
10
Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study.甲状腺乳头状癌中央区淋巴结转移的危险因素:一项回顾性研究。
Front Endocrinol (Lausanne). 2023 Nov 17;14:1288527. doi: 10.3389/fendo.2023.1288527. eCollection 2023.

本文引用的文献

1
Overview on the endoscopic treatment for obesity: A review.肥胖的内镜治疗概述:综述。
World J Gastroenterol. 2023 Oct 28;29(40):5526-5542. doi: 10.3748/wjg.v29.i40.5526.
2
Empirical dietary inflammatory index and lifestyle inflammation score relationship with obesity: A population-based cross-sectional study.经验性饮食炎症指数和生活方式炎症评分与肥胖的关系:一项基于人群的横断面研究。
Food Sci Nutr. 2023 Sep 13;11(11):7341-7351. doi: 10.1002/fsn3.3660. eCollection 2023 Nov.
3
Thyroid nodule malignancy is associated with increased non-invasive hepatic fibrosis scores in metabolic subjects.甲状腺结节恶性肿瘤与代谢性疾病患者非侵入性肝纤维化评分增加有关。
Front Oncol. 2023 Oct 26;13:1233083. doi: 10.3389/fonc.2023.1233083. eCollection 2023.
4
CDK4 phosphorylation status and rational use for combining CDK4/6 and BRAF/MEK inhibition in advanced thyroid carcinomas.CDK4 磷酸化状态与 CDK4/6 和 BRAF/MEK 抑制联合应用于晚期甲状腺癌的合理选择。
Front Endocrinol (Lausanne). 2023 Oct 26;14:1247542. doi: 10.3389/fendo.2023.1247542. eCollection 2023.
5
Laparoscopic Adrenalectomy: Tailoring Approaches for the Optimal Resection of Adrenal Tumors.腹腔镜肾上腺切除术:为肾上腺肿瘤的最佳切除量身定制手术方法。
Diagnostics (Basel). 2023 Oct 31;13(21):3351. doi: 10.3390/diagnostics13213351.
6
High-fat diet and obesity are associated with differential angiogenic gene expression in epithelial ovarian cancer.高脂肪饮食和肥胖与上皮性卵巢癌中血管生成基因表达的差异有关。
Gynecol Oncol. 2023 Dec;179:97-105. doi: 10.1016/j.ygyno.2023.11.002. Epub 2023 Nov 11.
7
Clinical characteristics and therapeutic response of differentiated thyroid carcinoma with obesity and diabetes.分化型甲状腺癌伴肥胖和糖尿病的临床特征及治疗反应。
BMC Cancer. 2023 Nov 8;23(1):1077. doi: 10.1186/s12885-023-11591-x.
8
Nonalcoholic Fatty Liver Disease and the Risk of Thyroid Cancer Among Young Adults in South Korea.非酒精性脂肪性肝病与韩国青年人群甲状腺癌风险的关系
J Clin Endocrinol Metab. 2024 Feb 20;109(3):e1095-e1104. doi: 10.1210/clinem/dgad575.
9
Potential Impact of Body Mass Index on the Clinical Outcome of Papillary Thyroid Cancer After High-Dose Radioactive Iodine Therapy.体重指数对大剂量放射性碘治疗后甲状腺乳头状癌临床结局的潜在影响。
Front Endocrinol (Lausanne). 2022 May 26;13:870530. doi: 10.3389/fendo.2022.870530. eCollection 2022.
10
The clinical importance of overweight or obesity on tumor recurrence in papillary thyroid carcinoma.超重或肥胖对甲状腺乳头状癌肿瘤复发的临床重要性。
Gland Surg. 2022 Jan;11(1):35-41. doi: 10.21037/gs-21-695.

甲状腺乳头状癌患者的体重指数与临床病理因素分析

Analysis of Body Mass Index and Clinicopathological Factors in Patients with Papillary Thyroid Carcinoma.

作者信息

Yan Wei, Luo Xue, Gao Qing-Jun, Chen Bing-Feng, Ye Hui

机构信息

Department of Thyroid Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, 550001, People's Republic of China.

Guizhou Medical University, Guiyang, 550001, People's Republic of China.

出版信息

Diabetes Metab Syndr Obes. 2024 May 13;17:2013-2019. doi: 10.2147/DMSO.S453468. eCollection 2024.

DOI:10.2147/DMSO.S453468
PMID:38765470
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11100954/
Abstract

OBJECTIVE

To analyze the correlation between body mass index (BMI) and clinicopathological factors of papillary thyroid cancer (PTC).

METHODS

The clinical data of patients with PCT who were hospitalized in the Department of Thyroid Surgery of the Affiliated Hospital of Guizhou Medical University from March 2023 to September 2023 were retrospectively collected, including age, gender, height, weight, BMI, v-raf murine sarcoma viral oncogene homolog B () gene mutation, tumor size, multifocus, Hashimoto's thyroiditis, lymph node metastasis and other clinicopathological factors. According to the World Health Organization (WHO) definition for Asian population, BMI≥25kg/m was obese group, 23≤BMI≤24.9kg/m was overweight group, 18.5≤BMI≤22.9kg/m was normal weight group, and BMI≤18.5kg/m was low weight group. The clinicopathological factors of overweight and obese patients with PTC were analyzed.

RESULTS

A total of 164 PTC patients were included, with an average BMI of (24.44±3.57) kg/m. Age of overweight and obese PTC patients (=1.978, =0.083); Gender of overweight and obese PTC patients ( value: 11.570, =0.004); Tumor size in overweight and obese PTC patients (=0.894, =0.411); gene mutation in overweight and obese PTC patients ( value: 1.452, =0.623); Multifocal lesions were found in overweight and obese patients ( value: 1.653, =0.201). Hashimoto's thyroiditis was found in overweight and obese PTC patients ( value: 1.147, =0.298). Overweight and obese patients with PTC had lymph node metastasis ( value: 1.690, =0.251).

CONCLUSION

Overweight and obesity in PTC patients are correlated with male, but not with age, tumor size, mutation, multifocality, Hashimoto's thyroiditis and lymph node metastasis.

摘要

目的

分析体重指数(BMI)与甲状腺乳头状癌(PTC)临床病理因素之间的相关性。

方法

回顾性收集2023年3月至2023年9月在贵州医科大学附属医院甲状腺外科住院的PTC患者的临床资料,包括年龄、性别、身高、体重、BMI、v-raf鼠肉瘤病毒癌基因同源物B()基因突变、肿瘤大小、多灶性、桥本甲状腺炎、淋巴结转移等临床病理因素。根据世界卫生组织(WHO)对亚洲人群的定义,BMI≥25kg/m为肥胖组,23≤BMI≤24.9kg/m为超重组,18.5≤BMI≤22.9kg/m为正常体重组,BMI≤18.5kg/m为低体重组。分析PTC超重和肥胖患者的临床病理因素。

结果

共纳入164例PTC患者,平均BMI为(24.44±3.57)kg/m。超重和肥胖PTC患者的年龄(=1.978,=0.083);超重和肥胖PTC患者的性别(值:11.570,=0.004);超重和肥胖PTC患者的肿瘤大小(=0.894,=0.411);超重和肥胖PTC患者的基因突变(值:1.452,=0.623);超重和肥胖患者发现多灶性病变(值:1.653,=0.201)。超重和肥胖PTC患者发现桥本甲状腺炎(值:1.147,=0.298)。PTC超重和肥胖患者有淋巴结转移(值:1.690,=0.251)。

结论

PTC患者超重和肥胖与男性相关,但与年龄、肿瘤大小、突变、多灶性、桥本甲状腺炎和淋巴结转移无关。